5 recruiting, 3 not yet recruiting, 2 unknown, 1 active not recruiting. 3 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Immune-Related Adverse Events: new trials by email Literature Review of Immune-Related Adverse Events trials Research Report on Immune-Related Adverse Events
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events Rituximab (RTX) - Immune-Related Adverse Events | Phase 1 | Recruiting | Inge Marie Svane | 25 | 2026-10-15 | 2026-10-20 |
| Cancer Nutrition Study - A Study of Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors High-Fermented Food Diet, HI-MAIZE 260 Resistant Starch - Solid Tumor Cancer, Immune-Related Adverse Events | Not applicable | Not yet recruiting | Thomas Jefferson University | 50 | 2026-10-01 | 2026-10-06 |
| Wucao Anfu Formula as Adjunctive Treatment for Immune Checkpoint Inhibitor-Related Rash Wucao Anfu Formula, Standard management - Immune Checkpoint Inhibitor-related Rash, Immune-related Adverse Events | Not applicable | Not yet recruiting | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine | 72 | 2026-09-05 | 2026-09-15 |
| Study on Biomarkers of Immune-Related Adverse Events Immune-Related Adverse Events | Not yet recruiting | Huazhong University of Science and Technology | 440 | 2026-04-01 | 2026-04-14 | |
| Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma adebrelimab combined with chemotherapy - Pathological Complete Remission, Objective Response Rate | Not applicable | Recruiting | The Second Hospital of Shandong University | 25 | 2024-12-09 | 2026-02-24 |
| Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients Immune Checkpoint Inhibitors - Immune-Related Adverse Events, Lupus Erythematosus, Systemic | Recruiting | Hospital Universitario Araba | 300 | 2024-01-08 | 2025-12-03 | |
| Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge Immune Checkpoint Inhibitors - Immune-Related Adverse Events | Recruiting | Peking Union Medical College Hospital | 500 | 2023-01-01 | 2026-03-06 | |
| Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) Rituximab, Tocilizumab - Immune-related Adverse Events, Advanced Solid Tumor | Phase 2 | Active not recruiting | Columbia University | 7 | 2020-09-25 | 2026-08-03 |
| PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study PD-1 inhibitor, Chemotherapy Drugs, Cancer - Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events | Unknown | Sungkyunkwan University | 4724 | 2020-07-01 | 2020-05-28 | |
| A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade Immune checkpoint blockade, Targeted therapy, Radiotherapy - Pneumonitis, Interstitial, Immunotherapy | Unknown | Universitaire Ziekenhuizen KU Leuven | 60 | 2020-02-01 | 2024-07-01 | |
| Longitudinal Cohort Study of Immune-Related Adverse Events in Solid Tumor Patients Treated With Immune Checkpoint Inhibitors Solid Tumor, Immune-Related Adverse Events | Recruiting | Shantou University Medical College | 940 | 2019-01-10 | 2026-01-28 |
Carcinoma, Non-Small-Cell Lung (1) · Exanthema (1) · Lung Diseases, Interstitial (1) · Lupus Erythematosus, Systemic (1) · Melanoma (1) · Myositis (1) · Neurotoxicity Syndromes (1) · Pathologic Complete Response (1) · Scleroderma, Systemic (1) · Sjogren's Syndrome (1)
Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Lung Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Nervous System Diseases (2) · Respiratory Tract Diseases (2) · Arthritis (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Chemically-Induced Disorders (1) · Connective Tissue Diseases (1) · Disease Attributes (1)
Immune Checkpoint Inhibitors (4) · Rituximab (2) · pembrolizumab (2) · Afatinib (1) · Antineoplastic Agents (1) · Carboplatin (1) · Cisplatin (1) · Crizotinib (1) · Docetaxel (1) · Drug Therapy (1) · Erlotinib Hydrochloride (1) · Gefitinib (1) · Gemcitabine (1) · Mitomycin (1) · Nivolumab (1)
Columbia University (1) · First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (1) · Hospital Universitario Araba (1) · Huazhong University of Science and Technology (1) · Inge Marie Svane (1) · Peking Union Medical College Hospital (1) · Shantou University Medical College (1) · Sungkyunkwan University (1) · The Second Hospital of Shandong University (1) · Thomas Jefferson University (1) · Universitaire Ziekenhuizen KU Leuven (1)
China (3) · Belgium (1) · Denmark (1) · Spain (1) · United States (1)
Brian Henick, MD (1) · Els Wauters, MD, PhD (1) · Ju-Young Shin, PhD (1) · Khvaramze Shaverdashvili, M.D. PhD (1) · Yunpeng Zhao, doctor (1)